Preclinical CRO in Oncology Research

Pharmatest offers translational models to test the efficacy of your oncology drug candidates. Our comprehensive preclinical oncology services include in vitro assays, in vivo efficacy models, radiotherapy testing service and ex vivo imaging technologies.

Pharmatest is a CRO specialized in orthotopic and metastasis models, and as bone experts we have special expertise in bone metastasis models. The major advantage of these models is the proper tissue microenvironment that is known to affect tumor properties and drug resistance. This increases substantially the clinical relevance and predictivity over traditionally used subcutaneous models that lack the proper microenvironment.

The following table lists cancer cell lines that are available in Pharmatest for orthotopic and/or metastasis models.

Xenograft Models

With human cancer cell lines
Immunodeficient Mice
Humanized Mice

BreastMCF-7, BT474, MDA-MB-231(SA)
FibrosarcomaHT-1080
LungA549
Pancreatic BxPC-3, Capan-1, Panc-1, MiaPaca-2
ProstateLNCaP, VCap, PC-3, 22Rv1

Xenograft Models

With human cancer cell lines
Immunodeficient Mice
Humanized Mice

BreastMCF-7, BT474, MDA-MB-231(SA)
BT-474
MDA-MB-231(SA)
FibrosarcomaHT-1080
LungA549
Pancreatic A549, Capan-1, Panc-1, MiaPaca-2
Capan-1
Panc-1
MiaPaca-2
ProstateLNCaP, VCap, PC-3, 22Rv1
VCaP
PC-3
22Rv1

Syngeneic Models

With mouse cancer cell lines
Immunocompetent Mice

Breast4T1
BladderMBT-02
ColonCT26wt
LungKLN-205
Multiple Myeloma5TGM1
RenalRenca
Ovarian cancerHM-1

In vitro cancer cell-based assays

All cancer cell lines listed above are also available for in vitro cancer cell culture assays and subcutaneous animal models. In addition, we would be happy to set up new models for you including cancer cell lines that would be of interest to you and are not listed in the table. If your focus is on cancer bone metastases, we would also like to invite you to take a look at our in vitro osteoclast assays that are useful for testing novel cancer drug compounds targeting osteoclasts to inhibit the vicious cycle of cancer-induced bone disease.

In vitro cancer cell-based assays

Contact an Expert